What drove AYA.AX stock higher on 12 Jan 2026?

AYA.AX stock rose after increased buying interest in AI healthcare names, a close at A$5.01 and technical strength near the 50-day average. Volume of 657,575.00 supported the move, though no single news release was cited.

What is Meyka AI's view on AYA.AX stock?

Meyka AI rates AYA.AX with a score out of 100: 66.91 (Grade B, suggestion HOLD). The grade factors in benchmarks, sector performance, financial growth, key metrics and analyst consensus.

What price targets exist for AYA.AX stock?

Meyka AI's forecast model projects A$6.67 at one year and A$13.09 at three years, implying a one-year upside of about 33.05% from A$5.01. Forecasts are model-based projections and not guarantees.

What are the main risks for AYA.AX stock?

Key risks include limited revenue scale, negative EPS (TTM -0.18), high valuation ratios such as PB 22.02, and execution risk for clinical roll-outs and reimbursement.

AU Stocks

AYA.AX Artrya Limited ASX +9.39% to A$5.01 on 12 Jan 2026: AI stock outlook

ByHuzaifa Zahoor January 12, 2026January 12, 2026

AYA.AX stock led today’s AI health-tech moves after Artrya Limited (AYA.AX) closed at A$5.01, up 9.39% on 12 Jan 2026 as the ASX session ended. Trading volume reached 657,575.00 and the day range was A$4.78–A$5.24, showing renewed investor interest in Artrya’s Salix AI. The stock’s 50-day average is A$3.80 and the 200-day average is A$2.01, signalling a strong momentum shift for this Australian healthcare AI name. We examine valuation, technicals, Meyka AI grade and the forecast that underpins short and medium-term price targets.